Y-mAbs Therapeutics, Inc. (YMAB)
YMAB moved a median of -0.20% 30 minutes after news, and -0.25% by the close. How YMAB actually reacts to news — the realized, point-in-time move the market made, measured across 226 labeled events over the last three years with zero look-ahead.
YMAB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 38% | 202 |
| 30-min | -0.20% | 39% | 203 |
| 60-min | -0.32% | 39% | 203 |
| to close | -0.25% | 34% | 203 |
| Middle 50% of YMAB reactions | -1.56% to +0.50% |
|---|---|
| Median reaction (30-min) | -0.20% |
| Measured reactions | 226 |
Half of all Y-mAbs Therapeutics, Inc. news events land between -1.56% and +0.50% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How YMAB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 20 | 0.00% | 65% | +0.12% |
| Coverage initiations | 15 | +1.07% | 60% | -3.92% |
| Rating reiterations | 40 | 0.00% | 53% | +0.44% |
| Price-target cuts | 10 | +0.41% | 80% | +3.71% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how YMAB ranks against every other measured name →
That’s how YMAB usually reacts — get an email when it moves on news →Email me when YMAB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to YMAB's baseline. Nothing else.
Recent YMAB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Y-mAbs Therapeutics, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Y-mAbs Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Y-mAbs Therapeutics, For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Y-mAbs Therapeutics, | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Y-mAbs Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 10-Q Y-mAbs Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.06% | +0.00% | |
| Form 8-K Y-mAbs Therapeutics, For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | +0.00% | |
| Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Press release | GlobeNewswire | -0.06% | +0.00% | |
| Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 | Press release | GlobeNewswire | +0.23% | +0.12% | |
| Form 8-K Y-mAbs Therapeutics, For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | +0.00% | |
| SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics | Press release | GlobeNewswire | +0.00% | -0.12% | |
| YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | -0.09% | +0.00% | |
| Form 8-K Y-mAbs Therapeutics, For: Jul 11 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | +2.35% | |
| Form ARS Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.18% | +4.18% | |
| Form DEF 14A Y-mAbs Therapeutics, For: Jul 11 | SEC filing · Form DEF | SEC EDGAR | +0.18% | +4.18% | |
| Form DEFA14A Y-mAbs Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.18% | +4.18% | |
| Form 8-K Y-mAbs Therapeutics, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +0.91% | +4.53% | |
| Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline | Press release | GlobeNewswire | +0.91% | +4.53% | |
| Advocacy-led Consensus Sets Path to Better High-Risk Neuroblastoma Care | Press release | PR Web | — | +0.00% | |
| Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting | Press release | GlobeNewswire | -2.16% | +0.46% | |
| Form 10-Q Y-mAbs Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +6.70% | -7.14% | |
| Form 8-K Y-mAbs Therapeutics, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +6.70% | -7.14% | |
| Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments | Press release | GlobeNewswire | +6.70% | -7.14% | |
| Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 | Press release | GlobeNewswire | +6.70% | -7.14% | |
| Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®) | Press release | GlobeNewswire | +0.38% | -0.77% | |
| Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 | Press release | GlobeNewswire | +2.02% | -8.31% | |
| Form 10-K/A Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.90% | -0.47% | |
| Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting | Press release | GlobeNewswire | +0.00% | +3.68% | |
| Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma | Press release | GlobeNewswire | -1.47% | +0.24% | |
| Form 10-K Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.14% | +13.24% | |
| Form 8-K Y-mAbs Therapeutics, For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +1.14% | +13.24% | |
| Form S-8 Y-mAbs Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +1.14% | +13.24% | |
| Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments | Press release | GlobeNewswire | +1.14% | +13.24% | |
| Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications | Press release | GlobeNewswire | +0.81% | -6.15% | |
| Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 | Press release | GlobeNewswire | -0.41% | -6.38% | |
| Y-mAbs to Present at the Oppenheimer 35?? Annual Life Sciences Conference | Press release | GlobeNewswire | -0.32% | -0.96% | |
| Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting | Press release | GlobeNewswire | +0.48% | -3.71% | |
| Form 8-K Y-mAbs Therapeutics, For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -2.63% | -4.97% | |
| Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities | Press release | GlobeNewswire | -0.35% | -4.70% | |
| Form 8-K Y-mAbs Therapeutics, For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | -4.70% | |
| Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit | Press release | GlobeNewswire | -0.35% | -4.70% | |
| Y-mAbs Provides Strategic Business Update and 2025 Priorities | Press release | GlobeNewswire | -0.35% | -4.70% | |
| Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.36% | -1.94% | |
| Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting | Press release | GlobeNewswire | -0.33% | -3.30% | |
| Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference | Press release | GlobeNewswire | -0.18% | +9.39% | |
| Form 10-Q Y-mAbs Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.46% | +12.17% | |
| Form 8-K Y-mAbs Therapeutics, For: Nov 08 | SEC filing · Form 8-K | SEC EDGAR | -7.46% | +12.17% | |
| Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments | Press release | GlobeNewswire | -7.46% | +12.17% | |
| Form 8-K Y-mAbs Therapeutics, For: Oct 29 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | +2.27% | |
| Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan | Press release | GlobeNewswire | -0.14% | +2.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the YMAB section they belong to.
Where else YMAB is measured.
YMAB earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GSRX INDUSTRIES INC (GSRX) | 226 | 0.00% | 19% |
| TETRALOGIC PHARMS CORP (TLOG) | 226 | +0.20% | 52% |
| Aurinia Pharmaceuticals Inc - Common Shares (AUPH) | 224 | +0.13% | 54% |
| Cel-Sci Corporation (CVM) | 224 | -0.54% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Y-mAbs Therapeutics, Inc.'s median reaction calculated?
Every labeled YMAB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 226 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of YMAB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does YMAB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.